Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) (DBCOND0036072)

Identifiers

Synonyms

Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT00489203	Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer	Beclomethasone dipropionate Methotrexate Tacrolimus	supportive_care	2	completed
NCT00003190	Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia	Cytarabine Daunorubicin Etoposide Valspodar	treatment	3	completed
NCT01233921	Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer	Palifermin	supportive_care	Not Available	completed
NCT01342887	Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Cyclosporine Etoposide Mitoxantrone Pravastatin	treatment	1 / 2	terminated
NCT00112853	Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia	Etoposide Tipifarnib	treatment	1	completed
NCT00890747	Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy	Sunitinib	treatment	1	completed
NCT00095797	XK469R in Treating Patients With Refractory Hematologic Cancer	No drug interventions	treatment	1	completed
NCT00470197	Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia	Alvocidib Cytarabine Mitoxantrone	treatment	1	completed
NCT01177371	High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma	Busulfan Cyclophosphamide Cyclosporine Methotrexate Methylprednisolone Methylprednisolone hemisuccinate	treatment	2	completed
NCT00602771	Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia	Etoposide Tipifarnib	treatment	2	completed
NCT01558778	Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	Not Available	withdrawn
NCT00666588	Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia	Bortezomib Bortezomib D-mannitol Cytarabine Etoposide Idarubicin	treatment	2	completed
NCT01550185	Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia	Eltrombopag	treatment	1	terminated
NCT01831232	Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes	Cytarabine Idarubicin Pravastatin	treatment	Not Available	completed
NCT00703300	Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia	2'-Deoxycytidine Bortezomib Bortezomib D-mannitol Decitabine	treatment	1	completed
NCT02144675	Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia	Choline magnesium trisalicylate Cytarabine Idarubicin	treatment	2	completed
NCT00062075	Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Romidepsin	treatment	2	completed
NCT00005799	Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer	Cyclosporine Fludarabine Mycophenolate mofetil Therapeutic allogeneic lymphocytes	treatment	Not Available	completed
NCT01083706	Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant	Azacitidine	treatment	2	completed
NCT01521936	Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy	No drug interventions	supportive_care	2	terminated
NCT01384513	A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies	Busulfan Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00093418	S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia	Tipifarnib	treatment	2	completed
NCT02299518	Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Cytarabine Escitalopram Etoposide Mitoxantrone Selinexor	treatment	1	completed
NCT00039117	Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia	Cytarabine Daunorubicin	treatment	1	completed
NCT00895934	Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML	Azacitidine Gemtuzumab ozogamicin Vorinostat	treatment	1 / 2	completed
NCT00863434	Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease	Clofarabine Cytarabine Filgrastim	treatment	2	terminated
NCT01839916	Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Therapeutic allogeneic lymphocytes	treatment	2	completed
NCT00045396	A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS)	Tipifarnib	treatment	2	completed
NCT00101296	Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Tipifarnib	treatment	1	completed
NCT00078858	Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1 / 2	completed
NCT00014235	Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	Not Available	completed
NCT01093586	Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Cyclophosphamide Cyclosporine Methylprednisolone Methylprednisolone hemisuccinate Mycophenolate mofetil	treatment	2	completed
NCT01246622	Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Cytarabine Lenalidomide	treatment	1	completed
NCT01141725	Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS	Bendamustine Idarubicin	treatment	1 / 2	completed
NCT00098826	SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes	Ispinesib	treatment	1	completed
NCT00352365	Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia	Lenalidomide	treatment	2	completed
NCT00839982	Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS	Clofarabine Cytarabine	treatment	1 / 2	completed
NCT00305773	Vorinostat in Treating Patients With Acute Myeloid Leukemia	Vorinostat	treatment	2	completed
NCT01529827	Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Fludarabine Melphalan Methotrexate Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT01199562	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant	Foscarnet Ganciclovir Valganciclovir	Not Available	Not Available	completed
NCT01101880	Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm	Clofarabine Cytarabine Filgrastim	treatment	2	completed
NCT00445744	Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome	Busulfan Cyclophosphamide Methotrexate Tacrolimus	treatment	Not Available	completed
NCT01159067	Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload	Deferasirox	supportive_care	2	terminated
NCT01798901	AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia	2'-Deoxycytidine AR-42 Decitabine	treatment	1	completed
NCT02049801	MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Binimetinib Cytarabine Idarubicin	treatment	1	terminated
NCT02071901	Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy	Eltrombopag	supportive_care	2	unknown_status
NCT01707004	Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Azacitidine Busulfan Cyclophosphamide Decitabine Filgrastim Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00049504	Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00027872	Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia	Tipifarnib	treatment	2	completed
NCT00060372	Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer	Ipilimumab Therapeutic allogeneic lymphocytes	treatment	1	completed
NCT01349972	Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	Alvocidib Cytarabine Daunorubicin Mitoxantrone	treatment	2	completed
NCT01031368	Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia	Clofarabine Cytarabine Dilanubicel Filgrastim	treatment	1	completed
NCT01801046	Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia	Cytarabine Mitoxantrone	treatment	1	terminated
NCT00040846	Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies	Alemtuzumab Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT00459212	GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia	GTI-2040	treatment	1	completed
NCT00077181	3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies	Cytarabine Triapine	treatment	1	completed
NCT00408681	Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant	Lithium carbonate	supportive_care	Not Available	completed
NCT02122081	Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Cyclophosphamide Methotrexate Tacrolimus	treatment	1	completed
NCT00540995	Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer	Beta-D-Glucose Busulfan Etoposide	treatment	1 / 2	terminated
NCT01523223	Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies	Therapeutic allogeneic lymphocytes	treatment	1	completed
NCT00098423	Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes	Cytarabine Tanespimycin	treatment	1	completed
NCT00357708	Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases	2'-Deoxycytidine Decitabine Vorinostat	treatment	1	completed
NCT00093743	Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1	completed
NCT01904643	Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Cytarabine Etoposide Lenalidomide Mitoxantrone	treatment	1	terminated
NCT01869803	Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia	Gemtuzumab ozogamicin	Not Available	Not Available	approved_for_marketing
NCT02316964	Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	2'-Deoxycytidine Aldesleukin Decitabine Natural Killer Cell	treatment	1	completed
NCT00795002	Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	Alvocidib Cytarabine Mitoxantrone	treatment	2	completed
NCT00070551	GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia	Cytarabine GTI-2040	treatment	1	completed
NCT01876953	Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia	Cytarabine Dasatinib Idarubicin	treatment	1 / 2	terminated
NCT00673153	Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia	Gemtuzumab ozogamicin Vorinostat	treatment	2	terminated
NCT00008177	Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1	completed
NCT01869777	Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia	No drug interventions	diagnostic	Not Available	completed
NCT01564277	Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies	Allopurinol Rasburicase	treatment	2	terminated
NCT01253447	AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	No drug interventions	treatment	2	completed
NCT01607645	Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS	2'-Deoxycytidine Cytarabine Decitabine Idarubicin	treatment	2	terminated
NCT00052598	Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant	Aldesleukin Therapeutic allogeneic lymphocytes	treatment	1 / 2	terminated
NCT00343798	A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies	Cyclophosphamide Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1	completed
NCT00357305	Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders	Cytarabine Etoposide Vorinostat	treatment	1	completed
NCT02030405	Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Ixazomib	treatment	2	terminated
NCT00462605	MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia	Entinostat Sargramostim	treatment	2	completed
NCT01768897	CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Cytarabine Devimistat Lipoic acid Mitoxantrone	treatment	1	completed
NCT00799461	Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications	No drug interventions	supportive_care	3	completed
NCT01548911	Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia	Gemtuzumab ozogamicin	treatment	2	withdrawn
NCT00089011	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer	Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00112593	Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	Not Available	completed
NCT00079378	Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	2'-Deoxycytidine Decitabine Valproic acid	treatment	1	completed
NCT01835288	Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Arsenic trioxide Arsenous acid	treatment	2	withdrawn
NCT00856388	Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Fludarabine Melphalan	treatment	Not Available	completed
NCT01174888	Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia	Beta-D-Glucose Bortezomib Bortezomib D-mannitol Cytarabine Etoposide Midostaurin Mitoxantrone	treatment	1	completed
NCT01127009	Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia	Beta-D-Glucose Bortezomib Bortezomib D-mannitol Cytarabine Etoposide Mitoxantrone	treatment	1	completed
NCT01175785	Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies	Cyclophosphamide Cyclosporine Dilanubicel Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT01822015	Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	Cytarabine Cytidine Idarubicin Sirolimus	treatment	0	completed
NCT01588015	Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	1	completed
NCT00357032	PXD101 in Treating Patients With Acute Myeloid Leukemia	Belinostat	treatment	2	completed
NCT00003875	Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia	Aldesleukin Busulfan Etoposide	treatment	2	completed
NCT01076270	Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Filgrastim Plerixafor	treatment	Not Available	terminated
NCT00331513	Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes	Idarubicin Vorinostat	treatment	1	completed
NCT01872819	Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay	No drug interventions	treatment	Not Available	completed
NCT02029417	Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia	2'-Deoxycytidine Cytarabine Decitabine Omacetaxine mepesuccinate	treatment	2	terminated
NCT01820624	Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Lithium carbonate Tretinoin	treatment	1	completed
NCT00085124	Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia	Cytarabine Daunorubicin	treatment	3	completed
NCT02105116	AML Therapy With Irradiated Allogeneic Cells	Cytarabine Filgrastim Fludarabine	treatment	Not Available	terminated
NCT00084916	CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase	Menthol Temsirolimus	treatment	2	completed
NCT01519596	Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy	No drug interventions	supportive_care	Not Available	completed
NCT00045435	Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT00006363	Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia	Aldesleukin Busulfan Cytarabine Daunorubicin Etoposide Filgrastim Valspodar	treatment	3	completed
NCT01465386	Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission	Bortezomib Bortezomib D-mannitol	treatment	2	terminated
NCT01842139	Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission	Basiliximab Carboxymethylcellulose Hiltonol Incomplete Freund's adjuvant Lysine Polyinosinic-polycytidylic acid	treatment	1	completed
NCT00096122	Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia	Cytarabine Idarubicin Tipifarnib	treatment	1 / 2	completed
NCT00742625	Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia	Bortezomib Bortezomib D-mannitol Cytarabine Daunorubicin	treatment	1 / 2	completed
NCT00602225	Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Clofarabine Cytarabine Filgrastim	treatment	1 / 2	completed
NCT00387426	Sunitinib in Treating Patients With Idiopathic Myelofibrosis	Sunitinib	treatment	2	terminated
NCT00407966	Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	Alvocidib Cytarabine Mitoxantrone	treatment	2	completed
NCT00119366	Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	terminated
NCT01273766	Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies	Deferasirox	supportive_care	2	completed
NCT00860574	Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia	Fludarabine Methotrexate Tacrolimus Treosulfan	treatment	2	completed
NCT00052520	Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation	Aldesleukin Therapeutic allogeneic lymphocytes	treatment	1 / 2	completed
NCT00049582	Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia	2'-Deoxycytidine Decitabine	treatment	1	terminated
NCT00101231	Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia	Alvocidib	treatment	1	terminated
NCT00012376	Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer	Bryostatin 1 Sargramostim	treatment	1	completed
NCT01849276	Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML	Cytarabine Metformin	treatment	1	terminated
NCT02094794	Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML	Cyclophosphamide Etoposide	treatment	2	recruiting
NCT00039091	Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer	Ipilimumab	treatment	1	terminated
NCT00275080	Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia	2'-Deoxycytidine Decitabine Vorinostat	treatment	1	completed
NCT00131989	Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia	Sorafenib	treatment	1	completed
NCT00634244	Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Alvocidib Carboplatin Cytarabine Etoposide Mitoxantrone Sirolimus Topotecan	treatment	2	completed
NCT00005940	Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission	Busulfan Cyclophosphamide Cyclosporine Methotrexate	treatment	2	completed
NCT01839240	Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia	Azacitidine Cytarabine Mitoxantrone	treatment	1	completed
NCT00322101	Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia	Busulfan Cyclophosphamide Cyclosporine Fludarabine Methotrexate Mycophenolate mofetil Tacrolimus	treatment	3	completed
NCT00536601	High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors	Busulfan Carboplatin Carmustine Cyclophosphamide Etoposide Melphalan Thiotepa	treatment	Not Available	completed
NCT01159301	Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia	Entinostat Sorafenib	treatment	1	terminated
NCT00492401	Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia	2'-Deoxycytidine Decitabine	treatment	2	completed
NCT00087204	Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia	Becatecarin Rebeccamycin	treatment	1	completed
NCT01235572	Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy	No drug interventions	health_services_research	2	completed
NCT00103272	17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer	Bortezomib Bortezomib D-mannitol Tanespimycin	treatment	1	terminated
NCT01555268	Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia	Cytarabine Trebananib	treatment	1	completed
NCT00301769	SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia	SJG-136	treatment	1	terminated
NCT00795769	Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant	Ondansetron	supportive_care	2	completed
NCT02019069	CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	Cytarabine Daunorubicin	treatment	2	completed
NCT01056614	Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Fludarabine Methotrexate Tacrolimus	treatment	2	completed
NCT01652014	Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	withdrawn
NCT01869114	Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy	Azacitidine Sirolimus	treatment	2	active_not_recruiting
NCT01789255	Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies	Cyclosporine Methotrexate Tacrolimus Vorinostat	supportive_care	2	completed
NCT00475150	Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	Cediranib	treatment	2	completed
NCT02085408	Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia	Clofarabine Cytarabine Daunorubicin Decitabine	treatment	3	active_not_recruiting
NCT00301938	7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes	7-Hydroxystaurosporine Perifosine	treatment	1	completed